Prime Medicine Stock (NASDAQ:PRME)

Forecast Revenue Ownership Financials Chart

Previous Close

$4.21

52W Range

$1.11 - $5.94

50D Avg

$2.56

200D Avg

$2.67

Market Cap

$550.09M

Avg Vol (3M)

$3.66M

Beta

2.34

Div Yield

-

PRME Company Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

214

IPO Date

Oct 20, 2022

Website

PRME Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
Reportable Segment	$2.98M

Fiscal year ends in Dec 24 | Currency in USD

PRME Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$2.98M	-	-
Operating Income	$-202.47M	$-191.29M	$-116.54M
Net Income	$-195.88M	$-198.13M	$-121.82M
EBITDA	$-202.47M	$-193.76M	$-110.75M
Basic EPS	$-1.65	$-2.18	$-1.25
Diluted EPS	$-1.65	$-2.18	$-1.25

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
ADPT	Adaptive Biotechnologies Corporation
RXRX	Recursion Pharmaceuticals, Inc.
BEAM	Beam Therapeutics Inc.
VERV	Verve Therapeutics, Inc.
ACLX	Arcellx, Inc.
SANA	Sana Biotechnology, Inc.
CRBU	Caribou Biosciences, Inc.
THRD	Third Harmonic Bio, Inc.